UK-US drug deal: Industry claim of improved access for 15 400 patients is “PR spin,” say experts

Scritto il 20/11/2026
da Jacqui Wise

The pharmaceutical industry’s claims that changes to the National Institute for Health and Care Excellence’s (NICE) cost effectiveness thresholds have improved patient access to new medicines “only tells one side of the story,” health economists and policy experts have said.Earlier this year the threshold that NICE uses when assessing new medicines was raised from £20 000-£30 000 per quality adjusted life year (QALY) to £25 000-£35 000 as part of the US-UK trade deal after pressure from Donald Trump.1The Association of the British Pharmaceutical Industry (ABPI) said in a new report that 15 426 additional patients will be eligible for treatment each year because of improved access to new medicines under the changes.2The industry body collects feedback from pharmaceutical companies on completion of their NICE appraisals to produce a Continuous NICE Implementation Evaluation (Connie) report. Its fifth Connie report includes 183 appraisals completed from August 2022 to August 2026, although...